PubMed:23946704 JSONTXT

{"project":"Allie","denotations":[{"id":"SS1_23946704_2_0","span":{"begin":406,"end":438},"obj":"expanded"},{"id":"SS2_23946704_2_0","span":{"begin":440,"end":444},"obj":"abbr"},{"id":"SS1_23946704_4_0","span":{"begin":501,"end":525},"obj":"expanded"},{"id":"SS2_23946704_4_0","span":{"begin":527,"end":530},"obj":"abbr"},{"id":"SS1_23946704_4_1","span":{"begin":549,"end":590},"obj":"expanded"},{"id":"SS2_23946704_4_1","span":{"begin":592,"end":597},"obj":"abbr"},{"id":"SS1_23946704_5_0","span":{"begin":793,"end":841},"obj":"expanded"},{"id":"SS2_23946704_5_0","span":{"begin":843,"end":849},"obj":"abbr"},{"id":"SS1_23946704_5_1","span":{"begin":879,"end":909},"obj":"expanded"},{"id":"SS2_23946704_5_1","span":{"begin":911,"end":915},"obj":"abbr"}],"relations":[{"id":"AE1_23946704_2_0","pred":"abbreviatedTo","subj":"SS1_23946704_2_0","obj":"SS2_23946704_2_0"},{"id":"AE1_23946704_4_0","pred":"abbreviatedTo","subj":"SS1_23946704_4_0","obj":"SS2_23946704_4_0"},{"id":"AE1_23946704_4_1","pred":"abbreviatedTo","subj":"SS1_23946704_4_1","obj":"SS2_23946704_4_1"},{"id":"AE1_23946704_5_0","pred":"abbreviatedTo","subj":"SS1_23946704_5_0","obj":"SS2_23946704_5_0"},{"id":"AE1_23946704_5_1","pred":"abbreviatedTo","subj":"SS1_23946704_5_1","obj":"SS2_23946704_5_1"}],"text":"Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.\nSTUDY OBJECTIVES: This double-blind study evaluated the efficacy and safety of modafinil for treating excessive daytime sleepiness in Japanese patients with obstructive sleep apnea syndrome (OSAS).\nMETHODS: Patients with residual excessive sleepiness (Epworth Sleepiness Scale [ESS] ≥ 11) on optimal nasal continuous positive airway pressure (nCPAP) therapy (apnea-hypopnea index ≤ 10) were randomized to either 200 mg modafinil (n = 52) or placebo (n = 62) once daily for 4 weeks. Outcomes included baseline-week 4 changes in ESS total score, sleep latency on maintenance of wakefulness test (SL-MWT), nocturnal polysomnography, Pittsburgh Sleep Quality Index (PSQI), and safety.\nRESULTS: All 114 randomized patients completed the study. Mean change in ESS total score (-6.6 vs -2.4, p \u003c 0.001) and SL-MWT (+2.8 vs -0.4 minutes, p = 0.009) were significantly greater with modafinil than with placebo. ESS total score decreased from \u003e 11 to \u003c 11 at the final assessment in 69.2% of modafinil-treated patients and 30.6% of placebo-treated patients (p \u003c 0.001). Corresponding rates at week 1 were 57.7% and 33.9% (p = 0.014). Changes in nocturnal polysomnography, PSQI, and apnea-hypopnea index from baseline to the final assessment were similar in both groups. Adverse drug reactions occurred in 36.5% and 22.6% of patients in the modafinil and placebo groups, respectively (p = 0.146).\nCONCLUSIONS: Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy."}

{"project":"PubmedHPO","denotations":[{"id":"T1","span":{"begin":279,"end":284},"obj":"HP_0000618"},{"id":"T2","span":{"begin":351,"end":379},"obj":"HP_0002189"},{"id":"T3","span":{"begin":406,"end":429},"obj":"HP_0002870"},{"id":"T4","span":{"begin":418,"end":429},"obj":"HP_0010535"},{"id":"T5","span":{"begin":424,"end":429},"obj":"HP_0002104"}],"text":"Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.\nSTUDY OBJECTIVES: This double-blind study evaluated the efficacy and safety of modafinil for treating excessive daytime sleepiness in Japanese patients with obstructive sleep apnea syndrome (OSAS).\nMETHODS: Patients with residual excessive sleepiness (Epworth Sleepiness Scale [ESS] ≥ 11) on optimal nasal continuous positive airway pressure (nCPAP) therapy (apnea-hypopnea index ≤ 10) were randomized to either 200 mg modafinil (n = 52) or placebo (n = 62) once daily for 4 weeks. Outcomes included baseline-week 4 changes in ESS total score, sleep latency on maintenance of wakefulness test (SL-MWT), nocturnal polysomnography, Pittsburgh Sleep Quality Index (PSQI), and safety.\nRESULTS: All 114 randomized patients completed the study. Mean change in ESS total score (-6.6 vs -2.4, p \u003c 0.001) and SL-MWT (+2.8 vs -0.4 minutes, p = 0.009) were significantly greater with modafinil than with placebo. ESS total score decreased from \u003e 11 to \u003c 11 at the final assessment in 69.2% of modafinil-treated patients and 30.6% of placebo-treated patients (p \u003c 0.001). Corresponding rates at week 1 were 57.7% and 33.9% (p = 0.014). Changes in nocturnal polysomnography, PSQI, and apnea-hypopnea index from baseline to the final assessment were similar in both groups. Adverse drug reactions occurred in 36.5% and 22.6% of patients in the modafinil and placebo groups, respectively (p = 0.146).\nCONCLUSIONS: Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy."}

{"project":"Linmchun_800_3","denotations":[{"id":"T1","span":{"begin":440,"end":444},"obj":"DP"},{"id":"T2","span":{"begin":406,"end":438},"obj":"DP"},{"id":"T3","span":{"begin":174,"end":206},"obj":"DP"},{"id":"T4","span":{"begin":1755,"end":1759},"obj":"DP"},{"id":"T5","span":{"begin":34,"end":43},"obj":"CI"},{"id":"T6","span":{"begin":328,"end":337},"obj":"CI"},{"id":"T7","span":{"begin":668,"end":677},"obj":"CI"},{"id":"T8","span":{"begin":690,"end":697},"obj":"CI"},{"id":"T9","span":{"begin":1122,"end":1131},"obj":"CI"},{"id":"T10","span":{"begin":1142,"end":1149},"obj":"CI"},{"id":"T11","span":{"begin":1231,"end":1240},"obj":"CI"},{"id":"T12","span":{"begin":1271,"end":1278},"obj":"CI"},{"id":"T13","span":{"begin":1579,"end":1588},"obj":"CI"},{"id":"T14","span":{"begin":1659,"end":1668},"obj":"CI"},{"id":"T15","span":{"begin":1593,"end":1600},"obj":"CI"}],"text":"Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.\nSTUDY OBJECTIVES: This double-blind study evaluated the efficacy and safety of modafinil for treating excessive daytime sleepiness in Japanese patients with obstructive sleep apnea syndrome (OSAS).\nMETHODS: Patients with residual excessive sleepiness (Epworth Sleepiness Scale [ESS] ≥ 11) on optimal nasal continuous positive airway pressure (nCPAP) therapy (apnea-hypopnea index ≤ 10) were randomized to either 200 mg modafinil (n = 52) or placebo (n = 62) once daily for 4 weeks. Outcomes included baseline-week 4 changes in ESS total score, sleep latency on maintenance of wakefulness test (SL-MWT), nocturnal polysomnography, Pittsburgh Sleep Quality Index (PSQI), and safety.\nRESULTS: All 114 randomized patients completed the study. Mean change in ESS total score (-6.6 vs -2.4, p \u003c 0.001) and SL-MWT (+2.8 vs -0.4 minutes, p = 0.009) were significantly greater with modafinil than with placebo. ESS total score decreased from \u003e 11 to \u003c 11 at the final assessment in 69.2% of modafinil-treated patients and 30.6% of placebo-treated patients (p \u003c 0.001). Corresponding rates at week 1 were 57.7% and 33.9% (p = 0.014). Changes in nocturnal polysomnography, PSQI, and apnea-hypopnea index from baseline to the final assessment were similar in both groups. Adverse drug reactions occurred in 36.5% and 22.6% of patients in the modafinil and placebo groups, respectively (p = 0.146).\nCONCLUSIONS: Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy."}

{"project":"luoyt2021_800_3","denotations":[{"id":"T1","span":{"begin":34,"end":43},"obj":"CI"},{"id":"T10","span":{"begin":1755,"end":1759},"obj":"DP"},{"id":"T11","span":{"begin":174,"end":206},"obj":"DP"},{"id":"T2","span":{"begin":1659,"end":1668},"obj":"CI"},{"id":"T3","span":{"begin":1579,"end":1588},"obj":"CI"},{"id":"T4","span":{"begin":1231,"end":1240},"obj":"CI"},{"id":"T5","span":{"begin":1122,"end":1131},"obj":"CI"},{"id":"T6","span":{"begin":668,"end":677},"obj":"CI"},{"id":"T7","span":{"begin":328,"end":337},"obj":"CI"},{"id":"T8","span":{"begin":406,"end":438},"obj":"DP"},{"id":"T9","span":{"begin":440,"end":444},"obj":"DP"},{"id":"T12","span":{"begin":1593,"end":1600},"obj":"CI"},{"id":"T13","span":{"begin":1271,"end":1278},"obj":"CI"},{"id":"T14","span":{"begin":1142,"end":1149},"obj":"CI"},{"id":"T15","span":{"begin":690,"end":697},"obj":"CI"}],"text":"Efficacy and safety of adjunctive modafinil treatment on residual excessive daytime sleepiness among nasal continuous positive airway pressure-treated japanese patients with obstructive sleep apnea syndrome: a double-blind placebo-controlled study.\nSTUDY OBJECTIVES: This double-blind study evaluated the efficacy and safety of modafinil for treating excessive daytime sleepiness in Japanese patients with obstructive sleep apnea syndrome (OSAS).\nMETHODS: Patients with residual excessive sleepiness (Epworth Sleepiness Scale [ESS] ≥ 11) on optimal nasal continuous positive airway pressure (nCPAP) therapy (apnea-hypopnea index ≤ 10) were randomized to either 200 mg modafinil (n = 52) or placebo (n = 62) once daily for 4 weeks. Outcomes included baseline-week 4 changes in ESS total score, sleep latency on maintenance of wakefulness test (SL-MWT), nocturnal polysomnography, Pittsburgh Sleep Quality Index (PSQI), and safety.\nRESULTS: All 114 randomized patients completed the study. Mean change in ESS total score (-6.6 vs -2.4, p \u003c 0.001) and SL-MWT (+2.8 vs -0.4 minutes, p = 0.009) were significantly greater with modafinil than with placebo. ESS total score decreased from \u003e 11 to \u003c 11 at the final assessment in 69.2% of modafinil-treated patients and 30.6% of placebo-treated patients (p \u003c 0.001). Corresponding rates at week 1 were 57.7% and 33.9% (p = 0.014). Changes in nocturnal polysomnography, PSQI, and apnea-hypopnea index from baseline to the final assessment were similar in both groups. Adverse drug reactions occurred in 36.5% and 22.6% of patients in the modafinil and placebo groups, respectively (p = 0.146).\nCONCLUSIONS: Once-daily modafinil was effective and well tolerated for managing residual daytime sleepiness in Japanese OSAS patients with residual excessive daytime sleepiness on optimal nCPAP therapy."}